Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
S 0.105 −32.3% OMI 0.310 −1.6% BMM 4.02 +5.8% CGD 0.630 +10.5% OCG 0.260 −7.1% CAMB 0.950 −5.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 1.00 −2.9% SGQ 0.400 +33.3% AMCO 0.225 −10.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.395 −1.2% LIB 0.780 −14.3% SMY 0.290 +23.4% S 0.105 −32.3% OMI 0.310 −1.6% BMM 4.02 +5.8% CGD 0.630 +10.5% OCG 0.260 −7.1% CAMB 0.950 −5.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 1.00 −2.9% SGQ 0.400 +33.3% AMCO 0.225 −10.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.395 −1.2% LIB 0.780 −14.3% SMY 0.290 +23.4%
Other

Canopy Growth Expands Spectrum Therapeutics Portfolio in Australia with New Softgels

By The Northwire Desk — AI Analysis Nov 18, 2025 · 07:00 WEED · 1.47 CANOPY GROWTH CORPORATION J
WEED · Price

Executive Summary

  • Canopy Growth introduced three new softgel capsule formats (Spectrum Yellow, Red, and Blue) to its Spectrum Therapeutics portfolio in Australia.
  • The softgels provide additional THC/CBD dosage options for medical patients, complementing existing oils, flower, and other brand products available in the market.
  • Expansion aligns with the company’s global medical strategy to broaden product formats and meet growing patient demand in established markets.

Key Details

  • New Products:
  • Spectrum Yellow Cannabis Oil Softgels – 20 mg CBD per capsule.
  • Spectrum Red Cannabis Oil Softgels – 10 mg THC per capsule.

  • Spectrum Blue Cannabis Oil Softgels – Balanced formulation of 2.5 mg THC and 3.75 mg CBD per capsule.

  • Market: Products are now available to Australian medical cannabis patients through authorized prescribers.

  • Strategic Rationale: Expansion of product formats in Australia is described as a “key driver” of Canopy Growth’s global medical strategy, aiming to increase convenience and choice for prescribers and patients.

  • Executive Comments:

  • CEO Luc Mongeau highlighted the softgels as deepening the company’s offering and reinforcing commitment to international markets.

  • SVP Global Medical Andrew Bevan noted patient demand for varied formats that deliver quality and convenience.

  • Complementary Portfolio: The new softgels augment existing Spectrum Therapeutics oils and flower, as well as products from Tweed, 7ACRES, and TWD already sold in Australia.

Notable Quotes

“Expanding our portfolio in established markets like Australia is a key driver of our global medical strategy,” – Luc Mongeau, Chief Executive Officer

“Patients continue to ask for a variety of formats that deliver both quality and convenience,” – Andrew Bevan, SVP, Global Medical

Read the original news release →

More from CANOPY GROWTH CORPORATION J

Jun 15, 2026 · 07:00

Balance sheet repair and MTL integration buy time, but margin compression and cash burn keep profitability distant.

Earnings Jun 08, 2026 · 07:30

Product line extension and award recognition fail to offset structural margin pressures and market skepticism.

Other May 29, 2026 · 07:00

Accounting Restatement and Management Cease Trade Order Loom Over Germany Expansion

Regulatory May 15, 2026 · 17:00

Canopy Growth’s accounting stumble is a self-inflicted wound that muddies the recovery narrative just as operational momentum was building.

Other May 14, 2026 · 08:45

Canopy Growth’s latest product tweak gets swept into a wider European boom story, but the stock’s rebound remains more about survival than fireworks.

M&A / Property May 07, 2026 · 07:30

Canopy Growth Expands Medical Portfolio as Integration Risks Linger Despite Liquidity Boost

Production / Operations